116 related articles for article (PubMed ID: 38030183)
1. Preoperative PI-RADS v2.1 Scoring System Improves Risk Classification in Patients Undergoing Radical Prostatectomy.
Fukui Y; Yamada Y; Sakamoto S; Horikoshi T; Zhao X; Sato K; Nanba S; Kubota Y; Kanesaka M; Fujimoto A; Shibata H; Goto Y; Sazuka T; Imamura Y; Uno T; Ichikawa T
Anticancer Res; 2023 Dec; 43(12):5705-5712. PubMed ID: 38030183
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of relationships between the final Gleason score, PI-RADS v2 score, ADC value, PSA level, and tumor diameter in patients that underwent radical prostatectomy due to prostate cancer.
Gündoğdu E; Emekli E; Kebapçı M
Radiol Med; 2020 Sep; 125(9):827-837. PubMed ID: 32266690
[TBL] [Abstract][Full Text] [Related]
3. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
4. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
[TBL] [Abstract][Full Text] [Related]
5. Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy.
Fujimoto A; Sakamoto S; Horikoshi T; Zhao X; Yamada Y; Rii J; Takeuchi N; Imamura Y; Sazuka T; Matsusaka K; Ikeda JI; Ichikawa T
Sci Rep; 2023 Jun; 13(1):10079. PubMed ID: 37344491
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2.
Kim R; Kim CK; Park JJ; Kim JH; Seo SI; Jeon SS; Lee HM
Korean J Radiol; 2019 Feb; 20(2):256-264. PubMed ID: 30672165
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Rajwa P; Mori K; Huebner NA; Martin DT; Sprenkle PC; Weinreb JC; Ploussard G; Pradere B; Shariat SF; Leapman MS
J Urol; 2021 Sep; 206(3):507-516. PubMed ID: 33904755
[TBL] [Abstract][Full Text] [Related]
8. Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
Park SY; Oh YT; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ
Eur Radiol; 2016 Aug; 26(8):2502-9. PubMed ID: 26560721
[TBL] [Abstract][Full Text] [Related]
9. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
10. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
11. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
12. MR-based prognostic nomogram for prostate cancer after radical prostatectomy.
Zhang YD; Wu CJ; Bao ML; Li H; Wang XN; Liu XS; Shi HB
J Magn Reson Imaging; 2017 Feb; 45(2):586-596. PubMed ID: 27654116
[TBL] [Abstract][Full Text] [Related]
13. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
Yilmaz EC; Lin Y; Belue MJ; Harmon SA; Phelps TE; Merriman KM; Hazen LA; Garcia C; Johnson L; Lay NS; Toubaji A; Merino MJ; Patel KR; Parnes HL; Law YM; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2024 Jan; 222(1):e2329964. PubMed ID: 37729551
[No Abstract] [Full Text] [Related]
14. [Implications of PI-RADS Version 1 and Updated Version 2 on the Scoring of Prostatic Lesions in Multiparametric MRI].
Haas M; Günzel K; Penzkofer T; Maxeiner A; Fischer T; Miller K; Hamm B; Asbach P; Cash H
Aktuelle Urol; 2016 Sep; 47(5):383-7. PubMed ID: 27680189
[TBL] [Abstract][Full Text] [Related]
15. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
[TBL] [Abstract][Full Text] [Related]
16. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
[TBL] [Abstract][Full Text] [Related]
17. PI-RADS v2 Findings of MRI and Positive Biopsy Core Percentage would Predict Pathological Extraprostatic Extension in Patients who Underwent Robot Assisted Radical Prostatectomy: A Retrospective Study.
Yamashita S; Kohjimoto Y; Sato H; Kikkawa K; Sonomura T; Hara I
Urol J; 2022 Dec; 19(6):438-444. PubMed ID: 35466392
[TBL] [Abstract][Full Text] [Related]
18. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract][Full Text] [Related]
19. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
20. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
